HVP and Seqirus partner to advance influenza vaccine research

The Human Vaccines Project, a non-profit public-private partnership focused on decoding the immune system to improve human health, and Seqirus, a company working in the prevention of influenza, announced that Seqirus is joining the Project’s Universal Influenza Vaccine Initiative (UIVI). Seqirus, owned by CSL Limited, has been working on flu vaccine developments and pandemic preparedness for more than a century, pioneering new technologies for rapidly producing the vaccines.

Launched in late 2017, the UIVI is a collaboration of global organisations and partners working together to accelerate the development of a universal vaccine that provides long-lasting protection against seasonal and pandemic influenza across demographics and geography. The Initiative fills a gap in flu vaccine research today by focusing on how the immune system responds to and develops immunological protection against multiple strains of flu.

“We are committed to collaborating with like-minded partners to advance understanding of the human response to influenza.”

Research will be conducted using biomedical and machine learning technologies to develop models of the immune system. The models will be artificial intelligence-based, so they will get smarter over time, rapidly accelerating vaccine research.

Wayne Koff, PhD, president and CEO of the Human Vaccines Project, said “While there have been recent advances in the development of better influenza vaccines, we need to continue to work towards more transformational solutions that provide higher levels of protection against multiple strains for longer periods of time”

Russell Basser, MD, senior vice president of research and development at Seqirus, said “Seqirus is pleased to bring its expertise to the Project, working alongside the eminent research organisations already involved

“Influenza remains one of our greatest global health threats and we are committed to collaborating with like-minded partners to advance understanding of the human response to influenza, and to discover new and innovative vaccine solutions.”